Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.
Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy (RIT) consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of these two interventions are currently under discussion. We now raise the question whether both RIT consolidation and rituximab maintenance should be used together aiming to augment the results achievable with R-chemotherapy.
Department of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland. Franz.Buchegger@chuv.ch.
Franz
F
Buchegger
Oliver W
OW
Press